Predictors of the CD24/CD11b Biomarker among Healthy Subjects

• Main Authors: Shiran Shapira, Gal Aiger, Amitay Ohayon, Dina Kazanov, Fatin Mdah, Marina Ben Shimon, Mori Hay-Levy, Lian Banon, Ido Laskov, Jacob Mashiah, Shahar Lev-Ari, Nadir Arber
• Format: Article
• Language: English
• Published: MDPI AG 2021-09-01
• Series: Journal of Personalized Medicine
• Subjects: CD24; prevention; screening test; biomarker
• Online Access: https://www.mdpi.com/2075-4426/11/9/939

The CD24 gene has raised considerable interest in tumor biology as a new prognostic factor and a biomarker for the early detection of cancer. There are currently no studies that assess predictors of CD24 in blood tests among healthy individuals. Our aims were (1) to evaluate predictors of the CD24/CD11b biomarker among healthy subjects and (2) to assess CD24/CD11b levels of participants with and without benign tumors. Our cohort included 1640 healthy subjects, aged 20–85, recruited at the Health Promotion and Integrated Cancer Prevention Center (ICPC) in the Tel Aviv Medical Center. Eligible subjects completed a detailed questionnaire on medical history and other epidemiologic information. CD24/CD11b expression in peripheral blood leukocytes (PBLs) obtained from blood samples of participants was analyzed by flow cytometry. Our results showed that the average levels of CD24/CD11b in healthy patients (22.8 ± 9.3) was statistically significant lower compared to subjects with benign cancers (26.1 ± 10.5, <i>p</i> < 0.001). Our multivariable analysis demonstrated that elevated levels of CRP (coefficient β: 1.98, <i>p</i> = 0.011) were significantly associated with high levels of CD24/CD11b expression among healthy participants. Other risk factors of cancer were not associated with elevated CD24 levels among healthy subjects. In conclusion, our findings may assist in further development and optimization of the CD24/CD11b biomarker to serve as a cancer screening test for early detection of cancer among the healthy population.